Natco is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $8.2B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Natco's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Lynparza | AstraZeneca / Merck | Generic | 2027 | Generic filed; in litigation | $3.3B |
| Imbruvica | AbbVie / Johnson & Johnson | Generic | 2032 | Blocked by court ruling (2021) | $4.9B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Natco's share of it.